HomePractical info & communicationsNewsOpen call to fund an EU-based novel antibiotic compound to progress to a clinical candidate, by the GNA NOW Consortium

Open call to fund an EU-based novel antibiotic compound to progress to a clinical candidate, by the GNA NOW Consortium

Share the article
Share on email
Share on twitter
Share on linkedin
Crédit : Pixabay

IMI AMR accelerator’s GNA NOW Consortium is looking for a novel antibiotic program to progress to Investigational
New Drug (IND).

Interested candidates are asked to submit a non-confidential Expression of Interest (EoI), which will be evaluated by the GNA NOW Review Committee. The top three submissions will be asked to provide a full proposal.

Important deadlines
• Expression of Interest submission: Friday 18 June 2021
• Programme proposal submission: Wednesday 25 August 2021
For more details on what the Consortium is looking for, what’s in it for interested candidates, and how to submit a proposal, please view the Open Call.

Make sure to also register for the GNA NOW Open Call webinar on Wednesday 12 May, during which more details will be provided and time will be made for questions and answers.

About GNA NOW
Established in July 2019, the GNA NOW Consortium is a European collaboration of 11 partners focused on progressing Gram-Negative antibiotics from lead optimization to the completion of Phase I trials.

Working under the AMR Accelerator umbrella, the project is funded by the Innovative Medicines Initiative (IMI) with inkind contributions from industry partner, Evotec.

Acknowledgement
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853979. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Disclaimer
This communication reflects the views of the GNA NOW Consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.

Project contacts
Dr. Kristina Orrling, Lygature: kristina.orrling@lygature.org
Dr. Sophie Lagrange, Evotec: Sophie.lagrange@evotec.com